OncoMatch/Clinical Trials/NCT05652920
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Is NCT05652920 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Ori-C101 for hepatocellular carcinoma.
Treatment: Ori-C101 — This is a Phase I, open-label, multi-center study to assess the safety, pharmacokinetics, and preliminary efficacy of GPC3-directed chimeric antigen receptor modified T cells injection (Ori-C101) in Advanced Hepatocellular Carcinoma(HCC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Biomarker criteria
Required: GPC3 expression positive by immunohistochemistry
Tumor tissue GPC3 expression positive by immunohistochemistry(IHC) at the local laboratory
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
Received at least two prior line of systemic therapy (included but not limited to target therapy, immunotherapy or chemotherapy) with radiologic disease progression during or following systemic therapy
Cannot have received: cell-based therapy (targeted GPC3 therapy, TCR-T therapy, CAR-T therapy)
Have received prior cell-based therapies such as targeted GPC3 therapy, TCR-T therapy, CAR-T therapy
Cannot have received: bone marrow or organ transplantation
Prior bone marrow or organ transplantation
Lab requirements
Blood counts
Inadequate bone marrow reserve or organ function [excluded]
Liver function
Child-Pugh A or B7, no history of hepatic encephalopathy
Child-Pugh A or B7, no history of hepatic encephalopathy; Inadequate bone marrow reserve or organ function [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify